Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPHELIA: Olaparib and Durvalumab in Head and Neck Cancer
NCT02882308Phase 2Completed
- Sponsor
- HeCOG
- Start
- Oct 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by HeCOG. Started Oct 2016; status: completed.
02
Drugs
olaparib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02882308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882308.